Druckenmiller’s Billion-Dollar Bet on Teva’s Turnaround

Stanley Druckenmiller’s Duquesne Family Office has placed a massive vote of confidence in pharmaceutical giant Teva, making it one of the fund’s largest holdings. The hedge fund legend has now increased his stake for four consecutive quarters, adding another million shares in the most recent period. This sustained accumulation by one of the world’s most astute investors raises a compelling question: what exactly is drawing such sophisticated capital to this particular drugmaker?

Financial Foundation Strengthens

Teva’s substantial efforts to streamline its operations over the past several years are yielding tangible results. The company has successfully reduced its net debt load significantly, achieving greater financial stability. This improved balance sheet provides the necessary footing to channel more resources into research and development initiatives. Management has reaffirmed ambitious 2027 targets, including a 30% operating margin and generating free cash flow exceeding $2.7 billion, signaling strong conviction in its financial trajectory.

Strategic Pivot Under New Leadership

A fundamental strategic shift is underway at Teva under the guidance of CEO Richard Francis. The company is moving decisively beyond its traditional focus on low-margin generic drugs toward a future built on innovative medicines. This transformation is already gaining traction, with products like AUSTEDO, AJOVY, and UZEDY demonstrating impressive growth. The momentum has been so strong that Teva was compelled to upwardly revise its 2025 revenue forecast for these specific divisions.

Should investors sell immediately? Or is it worth buying Teva?

Unexpected Tailwind for Generics Business

While innovation takes priority, Teva’s established generics division has recently received a significant, unforeseen boost. As of August 22, 2025, generic pharmaceuticals have been granted an exemption from new U.S. tariffs imposed on European drug products. This regulatory development provides a notable advantage for Teva’s extensive generics portfolio and its substantial export operations into the American market.

The critical question remains whether Teva’s dual strategy—combining a push into innovative blockbusters with a fortified generics operation—will justify the confidence of high-profile investors like Druckenmiller. Although the stock currently trades approximately 28% below its 52-week high, it has shown recent signs of recovery. With a Relative Strength Index (RSI) reading of 65, it is beginning to exhibit upward momentum. The success of this corporate transformation will ultimately be measured in the financial results of the coming quarters.